急性呼吸窘迫综合征中的右心室
该综述聚焦急性呼吸窘迫综合征(ARDS)中的右心室功能障碍(RVD)。ARDS尽管采用最佳标准治疗,合并死亡率仍约40%。当前治疗策略以改善氧合和肺顺应性、同时减少呼吸机相关肺损伤为基础;相对低氧血症可被良好耐受,氧合改善不一定转化为生存获益。中重度ARDS常出现右心室功能障碍,超声心动图可见的RVD患病率在不同研究中为22%至50%;RVD与死亡率之间无确切因果关系,但严重RVD与死亡率升高相关。缺氧性肺血管收缩、高碳酸血症和高驱动压有创通气是可对右心室功能产生不利影响的因素;用于前瞻性评估右心室的超声心动图标志物(定性和定量)尚未在足够把握度的研究中检验。
要点
- ARDS合并死亡率约40%,即使采用最佳标准治疗仍如此。
- 中重度ARDS中超声心动图可见的右心室功能障碍患病率为22%至50%。
- 严重右心室功能障碍与死亡率升高相关,但RVD与死亡率之间无确切因果关系。
- 缺氧性肺血管收缩、高碳酸血症和高驱动压有创通气是可对右心室功能产生不利影响的因素。
- 用于前瞻性评估右心室的超声心动图标志物(定性和定量)尚未在足够把握度的研究中检验。
适用人群与场景
- 中重度急性呼吸窘迫综合征(ARDS)患者。
研究设计与关键结果
- 综述指出ARDS合并死亡率约40%。
- 超声心动图可见的右心室功能障碍在中重度ARDS中的患病率在不同研究中为22%至50%。
- 严重右心室功能障碍与死亡率升高相关,但RVD与死亡率之间无确切因果关系。
- 缺氧性肺血管收缩、高碳酸血症和高驱动压有创通气是可对右心室功能产生不利影响的因素。
- 用于前瞻性评估右心室的超声心动图标志物(定性和定量)尚未在足够把握度的研究中检验。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为中重度ARDS常合并右心室功能障碍,严重右心室功能障碍与死亡率升高相关。
- 作者认为缺氧性肺血管收缩、高碳酸血症和高驱动压有创通气可对右心室功能产生不利影响。
- 作者指出用于前瞻性评估右心室的超声心动图标志物(定性和定量)尚未在足够把握度的研究中检验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
ARDS is associated with poor clinical outcomes, with a pooled mortality rate of approximately 40% despite best standards of care. Current therapeutic strategies are based on improving oxygenation and pulmonary compliance while minimizing ventilator-induced lung injury. It has been demonstrated that relative hypoxemia can be well tolerated, and improvements in oxygenation do not necessarily translate into survival benefit. Cardiac failure, in particular right ventricular dysfunction (RVD), is commonly encountered in moderate to severe ARDS and is reported to be one of the major determinants of mortality. The prevalence rate of echocardiographically evident RVD in ARDS varies across studies, ranging from 22% to 50%. Although there is no definitive causal relationship between RVD and mortality, severe RVD is associated with increased mortality. Factors that can adversely affect RV function include hypoxic pulmonary vasoconstriction, hypercapnia, and invasive ventilation with high driving pressure. It might be expected that early diagnosis of RVD would be of benefit; however, echocardiographic markers (qualitative and quantitative) used to prospectively evaluate the right ventricle in ARDS have not been tested in adequately powered studies. In this review, we examine the prognostic implications and pathophysiology of RVD in ARDS and discuss available diagnostic modalities and treatment options. We aim to identify gaps in knowledge and directions for future research that could potentially improve clinical outcomes in this patient population.
参考来源
- Zochios V, Parhar K, Tunnicliffe W, et al. The Right Ventricle in ARDS. Chest. 2017. PMID: 28267435. doi:10.1016/j.chest.2017.02.019
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。